Amyloid-Beta and Alzheimer’s Disease
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 2125
Special Issue Editors
Interests: Alzheimer's disease; amyloid-beta (Aβ); high-density lipoprotein; oxidative stress
Special Issues, Collections and Topics in MDPI journals
2. O-Force Co., Ltd., 3454 Irino Kuroshio-cho, Hata-gun, Kochi 789-1931, Japan
Interests: Alzheimer's disease; amyloid-beta (Aβ); high-density lipoprotein; oxidative stress
Special Issue Information
Dear Colleagues,
Alzheimer's disease (AD) is the most common neurodegenerative disorder. The pathological proteins primarily associated with AD are amyloid-beta (Aβ) and tau. The "amyloid cascade hypothesis" is currently the most widely accepted molecular mechanism underlying AD pathogenesis. It suggests that an imbalance in the production and clearance of Aβ in the brains of AD patients results in Aβ deposition and the formation of neurotoxic Aβ oligomers. Therefore, understanding the mechanisms behind Aβ production and clearance is crucial for developing effective strategies to slow or halt the progression of AD.
Based on the theory that Aβ accumulation and aggregation in the brain contribute to AD's onset and progression, anti-Aβ monoclonal antibodies have been developed and tested in clinical trials. This success has strengthened the amyloid-β hypothesis, positioning amyloid as a central factor in Alzheimer's disease. However, the amyloid cascade alone no longer fully explains AD development. It is now well recognized that neuroinflammation plays a significant role in AD pathogenesis.
This Special Issue focuses on the importance of amyloid-β research in understanding Alzheimer's disease and developing therapeutic agents. Additionally, we will explore other potential mechanisms, such as neuroinflammation, with an emphasis on the role of microglia and astrocytes. By doing so, we aim to provide a comprehensive understanding of Alzheimer's disease.
Potential topics include, but are not limited to, the following:
- Aβ production and assembly.
- Aβ/oxidative stress-induced neurotoxicity.
- Interactions between Aβ and tau in AD.
- Clearance mechanisms of Aβ.
- Anti-amyloid monoclonal antibodies and amyloid-related imaging abnormalities.
- Role of microglia and astrocytes in AD.
- Aβ/microglial-mediated neuroinflammation.
We look forward to your contributions.
Dr. Fumiaki Ito
Prof. Dr. Toshifumi Akizawa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer's disease (AD)
- amyloid-beta (Aβ)
- neurotoxicity of Aβ
- Tau protein
- Aβ phagocytosis
- Aβ clearance
- autophagy–lysosome system
- anti-Aβ monoclonal antibodies
- neuroinflammation in AD
- glial cells in AD
